CoChat

Angiotensin II‐receptor‐antagonists: Further evidence of fetotoxicity but not teratogenicity

Schaefer, Christof · 2003 · Birth Defects Research Part A: Clinical and Molecular Teratology
Cited by 129

The DOI matches its Crossref record.

Abstract

BACKGROUND: Like angiotensin converting enzyme (ACE) inhibitors angiotensin II (AT II)‐receptor‐antagonists may cause persistent or even lethal fetotoxic defects when used during the late second or third trimester. There are insufficient data on first‐trimester exposure to these substances in terms of teratogenicity. The two databases of the Berlin Teratology Information Service (TIS) were evaluated for pregnancy outcome following exposure to AT II‐receptor‐antagonists. One database covers case reports on newborns with congenital abnormalities identified after birth, in which drug‐effect associations can be evaluated retrospectively. The other enrolls women prospectively according to exposure to particular drugs during pregnancy, with follow‐up of pregnancy outcome. CASES: Five cases (four retrospective and one prospective) involving late‐pregnancy use of AT II‐receptor‐antagonists were recently reported to us, each of which included one or more of the following abnormalities: oligohydramnios/anhydramnios, anuria, hypoplastic skull bones, limb contractions, lung hypoplasia, and neonatal death. Among 37 prospectively enrolled first‐trimester‐exposed pregnancies there were 30 live births including one with a major malformation (cleft palate). One pregnancy was electively terminated after exencephaly had been diagnosed. CONCLUSIONS: AT II‐receptor‐antagonists may induce fetotoxic effects when used in the second and third trimesters. The available data on first‐trimester use do not strongly support a teratogenic potential. AT II‐receptor‐antagonists should not be used by pregnant women. In case of inadvertent exposure, therapy should be changed to the known antihypertensives of choice (e.g., metoprolol, methyldopa, and hydralazine) and fetotoxic effects should be ruled out by ultrasound. Treatment with AT II‐receptor‐antagonists during early pregnancy is not in itself an indication for termination of a wanted pregnancy. Birth Defects Research (Part A), 2003. © 2003 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bdra.10081

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 129

Metadata

Authors
Schaefer, C.
Venue
Birth Defects Research Part A: Clinical and Molecular Teratology
Publisher
Wiley
Published
2003-07-24
Volume
67
Issue
8
Pages
591-594
ISSN
  • 1542-0752 (ISSN-L)
  • 1542-0760
OpenAlex
W2071658329
Cited by
129
References
0
FWCI
5.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiotensin II‐receptor‐antagonists: Further evidence of fetotoxicity but not teratogenicity. https://app.cochat.ai/papers/10.1002/bdra.10081
The paper
Schaefer, C. (2003). Angiotensin II‐receptor‐antagonists: Further evidence of fetotoxicity but not teratogenicity. Birth Defects Research Part A: Clinical and Molecular Teratology. https://doi.org/10.1002/bdra.10081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.